Business Context and Reporting Period
Company: CryoLife, Inc. (Note: Metadata listed "Artivion, Inc." but filing is for CryoLife, Inc.)
Reporting Period: Quarterly Report (Form 10-Q) for the period ended June 30, 1997.
Business Overview: CryoLife specializes in cryopreservation of human tissues (heart valves, veins, orthopedic tissues) and medical devices. A significant event during the period was the acquisition of Ideas for Medicine, Inc. (IFM), a manufacturer of single-use cardiovascular products, on March 5, 1997.
Key Financial Metrics
| Metric | 3 Months Ended June 30, 1997 | 6 Months Ended June 30, 1997 |
|---|---|---|
| Total Revenues | $12,723,000 | $23,136,000 |
| Net Income | $1,160,000 | $2,112,000 |
| Earnings Per Share (EPS) | $0.12 | $0.21 |
| Cost of Preservation & Products | $4,550,000 (36% of Rev) | $7,976,000 (35% of Rev) |
| Operating Expenses (G&A + R&D) | $6,022,000 | $11,350,000 |
| Cash and Cash Equivalents | $208,000 (End of Period) | $208,000 (End of Period) |
| Net Working Capital | $16,627,000 | $16,627,000 |
| Current Ratio | 4.2 to 1 | 4.2 to 1 |
| Total Debt (Current + Long Term) | $15,907,000 | $15,907,000 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 31% for the quarter and 28% for the six-month period compared to 1996. This includes $1.6 million (quarter) and $2.1 million (six months) attributable to the IFM acquisition.
- Profitability: Net income rose 17% for the quarter ($1.16M vs $0.99M) and 19% for the six months ($2.11M vs $1.77M) compared to the prior year periods.
- Cash Flow: Operating cash flow turned negative, using $2.34 million for the six months ended June 30, 1997, compared to providing $0.15 million in the prior year. This was driven by increases in receivables, deferred preservation costs, and inventory.
- Balance Sheet: Total assets increased from $34.97 million to $47.94 million, primarily due to the acquisition of IFM (adding goodwill and intangibles) and increased working capital requirements.
- Debt: Long-term liabilities increased significantly from $2.8 million to $15.4 million due to borrowings for the IFM acquisition and new facility construction.
Guidance, Outlook, and Risks
- Outlook: Management believes current borrowing capacity and cash from operations will meet needs for the next 12 months, including funding for a new IFM facility and potential stock repurchases (up to 500,000 shares).
- Seasonality: Demand for human heart valve preservation is seasonal, peaking in the second and third quarters due to pediatric surgeries.
- Risks: Key risks include government regulation, competitive position, tissue availability, product development status, intellectual property protection, third-party reimbursement rates, and the successful integration of IFM operations.
- Unusual Items: The acquisition of IFM involved $4.5 million in cash and $5 million in convertible debentures. The filing notes the death of Board Member Rodney G. Lacy on July 19, 1997.
Investor Verification Checklist
- Acquisition Integration: Verify the operational and financial integration progress of Ideas for Medicine, Inc. (IFM) and the impact on future margins.
- Liquidity Position: Confirm the sufficiency of the revolving credit facility given the significant decrease in cash equivalents ($1.37M to $0.21M) and negative operating cash flow.
- Debt Obligations: Review the terms of the $5 million convertible debentures and the impact of interest expenses on future earnings.
- Working Capital Trends: Monitor the continued growth in deferred preservation costs and receivables to ensure they align with revenue collection cycles.
- Regulatory Environment: Assess any pending changes in government regulation regarding tissue preservation and reimbursement rates.